The Gross Law Firm notifies investors that a class action has commenced in the United States District Court for the District of Massachusetts on behalf of shareholders of Replimune Group, Inc. who purchased Securities between October 20, 2025 and April 10, 2026.
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) in connection with the BLA, the study design concerns previously communicated by the FDA were not addressed; (2) the Company had submitted data from an early unplanned analysis from RP1-104, which included only 40 patients (10% of the planned enrollment of 400 patients); (3) as a result, RPL-001-16 and RP1-104 both had deficiencies which were likely to cause the FDA to reject the BLA; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. Appointment as Lead Plaintiff is not required to partake in any recovery.
Shareholders have until October 5, 2026 to request that the court appoint them lead plaintiff.
To receive more information, please fill out the form.
